Browse funders

…afe, off-the-shelf treatment option that is currently used in 7 FDA-approved gene therapies. AVO-100 is a gene therapy that uses AAV with ca…

…e event data from 65,555 cancer patients were obtained from the FDA Adverse Event Reporting System (FAERS). Relative odds ratios (R…

…dates to international guidance, including ICH Q5A(R2), reflect FDA’s push to reduce animal-based biosafety testing in favor of mol…

… with an advanced solid cancer diagnosis defined as rare by the FDA (<200,000 patients diagnosed) who received any ICI-containing r…

…atification.Acknowledgements This study was partially funded by Kite, a Gilead Company. Additional support was provided by NIH R01CA…

… database spanned from 2011 (first authorization of ICIs by the FDA) to May 2025. Inclusion criteria included patients diagnosed wi…

…immunotherapeutic. The IND application was approved by both the FDA and NMPA, and Phase I trials were initiated in Q2 2025, offerin…

…al was approved by the Danish National Ethics Committee and the Danish Medicines Agency with the approval number 1905760. All approvals were obtained p…

… Journal for ImmunoTherapy of Cancer 2024;12(Suppl 2):A677–A678.FDA. Optimizing the dose of human prescription drugs and biological…

…g.Ethics Approval Study EIU-104101 is currently under review by FDA and will only begin enrollment upon clearance from relevant hea…

…immune recovery.Acknowledgements These trials are funded by the FDA, the LLS and the Brown Center for ImmunotherapyTrial Registrati…

…nvestigated whether targeting glycolysis using pramlintide,7 an FDA approved amylin analogue for type II Diabetes, can suppress EWS…